Article
Immunological effects of BCG as an adjuvant in autologous tumor vaccines.
Clinical immunology (Orlando, Fla.) - 1 Jan 2000
Li Q, Normolle D P, Sayre D M, Zeng X, Sun R, Jiang G, Redman B D, Chang A E
Abstract excerpt
The role of Bacillus Colmette-Guérin (BCG) as an adjuvant in autologous tumor vaccines was examined. In nine patients with renal cell cancer, irradiated tumor cells alone (wild-type, WT) or with BCG were inoculated intradermally into contralateral thighs. Seven to 10 days later, the draining vaccine-primed lymph nodes (WT-VPLN and BCG-VPLN) were excised. BCG increased the number of harvested VPLN cells by 10-fold...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.